Fulcrum director awarded 32,000 stock options
Fulcrum Therapeutics director Kate Haviland received a new stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Fulcrum Therapeutics director Kate Haviland received a new stock option grant. She was awarded options covering 32,000 shares of Fulcrum Therapeutics common stock at an exercise price of $3.6600 per share.
The option was granted as of June 30, 2026 and is scheduled to vest in full on the first anniversary of the grant date or, if earlier, immediately before the first annual meeting of stockholders after the grant date, assuming continued service. Following this grant, she holds options for 32,000 shares directly.
Insider Trade Summary
Grant/Award: 32,000 shares
Grant/Award
1 txn
Insider
Haviland Kate
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 32,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 32,000 contracts (Direct)
Footnotes (1)
- F1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Key Figures
Option grant size: 32,000 shares
Exercise price: $3.6600 per share
Underlying shares: 32,000 shares
+2 more
5 metrics
Option grant size
32,000 shares
Stock Option (right to buy) granted June 30, 2026
Exercise price
$3.6600 per share
Conversion or exercise price of stock options
Underlying shares
32,000 shares
Underlying common stock for the option grant
Total derivative holdings after grant
32,000 options
Total shares following transaction (derivative)
Option expiration
June 29, 2036
Expiration date of stock option grant
Key Terms
Stock Option (right to buy), Common Stock, exercise price, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 3.6600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-29T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"is scheduled to vest with respect to all shares on the first anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Fulcrum Therapeutics (FULC) director Kate Haviland receive in this Form 4 filing?
Kate Haviland received a new stock option grant for 32,000 shares of Fulcrum Therapeutics common stock. The options are part of her director compensation and give her the right to buy shares at a fixed exercise price if vesting conditions are met.
What is the exercise price of Kate Haviland’s Fulcrum Therapeutics stock options?
The options have an exercise price of $3.6600 per share. This is the fixed price at which she can buy Fulcrum Therapeutics common stock once the options vest and she chooses to exercise them, regardless of the market price at that time.
When do Kate Haviland’s Fulcrum Therapeutics options vest?
The options are scheduled to vest with respect to all 32,000 shares on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual meeting of stockholders after that date, provided she continues to serve through the vesting date.
What is the expiration date of the Fulcrum Therapeutics options granted to Kate Haviland?
The options expire on June 29, 2036. After this expiration date, any unexercised portion of the 32,000-share option grant will lapse, and she will no longer have the right to purchase Fulcrum Therapeutics shares under this grant.
How many Fulcrum Therapeutics derivative securities does Kate Haviland hold after this grant?
After this grant, she holds options representing 32,000 shares of Fulcrum Therapeutics common stock directly. These are derivative securities, meaning they provide a right to buy shares in the future rather than immediate share ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates